Jing Marantz

Jing L. Marantz joined Scholar Rock November 2022 as Chief Medical Officer, overseeing development and medical affairs. She has over 20 years of experience in the biopharmaceutical industry spanning R&D, business development, and commercial strategy in multiple specialties and rare diseases. Jing currently serves on the board of Arcturus Therapeutics (NASDAQ: ARCT). She was recently EVP and Chief Business Officer of Krystal Biotech, after serving on its board for a year. Prior to Krystal, Jing was Senior Vice President of Medical Affairs at Acceleron Pharma until its acquisition by Merck & Co., Inc. Jing has held leadership positions at Alnylam, Alexion, Biogen, ARIAD, and Millennium Pharmaceuticals across development, medical affairs, and business development. She was a management consultant with Strategic Decisions Group and briefly affiliated with Massachusetts General Hospital following a post-doctoral fellowship at the Dana-Farber Cancer Institute. She received her medical training from Tongji Medical College, a PhD in Biochemistry and Molecular Biology from Medical University of South Carolina, and an MBA from the University of California at Berkeley.